/
DCF Valuation
Base-case fair value
$83.20
Intrinsic $110.93 · 25% MOS
Current price: $44.95
Base-case summary
Our base-case DCF for Boston Scientific Corp (BSX) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 21.4% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $3.5B in trailing free cash flow, this produces an intrinsic value of $110.93 per share. A 25% safety margin gives a fair value of $83.20, suggesting the stock is currently 85% undervalued against the $44.95 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$3.5B
Cash & equivalents
$1.5B
Total debt
$11.0B
Shares outstanding
1.5B